Prodrugs: A challenge for the drug development
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abbott, 2010, Structure and function of the blood-brain barrier, Neurobiol Dis, 37, 13, 10.1016/j.nbd.2009.07.030
Afshar, 2009, Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer, Mol Cancer Ther, 8, 185, 10.1158/1535-7163.MCT-08-0652
Bagshawe, 2009, Targeting. the ADEPT story so far, Curr Drug Targets, 10, 152, 10.2174/138945009787354520
Baldwin, 2003, Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer, Arch Biochem Biophys, 409, 197, 10.1016/S0003-9861(02)00453-8
Battah, 2001, Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy, Bioconjugate Chem, 12, 980, 10.1021/bc010027n
Battah, 2006, Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy an in vitro study, Int J Biochem Cell Biol, 38, 1382, 10.1016/j.biocel.2006.02.001
Bean, 2008, Commercially available prostaglandin analogs for the reduction of intraocular pressure. similarities and differences, Surv Ophthalmol, 53, S69, 10.1016/j.survophthal.2008.08.012
Beaumont, 2003, Design of ester prodrugs to enhance oral absorption of poorly permeable compounds challenges to the discovery scientist, Curr Drug Metab, 4, 461, 10.2174/1389200033489253
Berger, 2003, Evaluation of dipeptide-derivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy, Bioorg Med Chem, 11, 1343, 10.1016/S0968-0896(02)00619-3
Bertolini, 2006, Paracetamol: New vista of an old drug, CNS Drug Rev, 12, 250, 10.1111/j.1527-3458.2006.00250.x
Bhandari, 2007, Evaluation of physicochemical properties, skin permeation and accumulation profiles of ketorolac fatty ester prodrugs, Biol Pharm Bull, 30, 2211, 10.1248/bpb.30.2211
Bissonnette, 2002, Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques, J Invest Dermatol, 119, 77, 10.1046/j.1523-1747.2002.01827.x
Bobeck, 2010, Advances in nucleoside monophosphate prodrugs as anti-HCV agents, Antivir Ther, 15, 935, 10.3851/IMP1667
Charkoudian, 2006, A prochelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation, J Am Chem Soc, 128, 12424, 10.1021/ja064806w
Chen, 2002, Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer, Curr Pharm Des, 8, 1405, 10.2174/1381612023394566
Chen, 2003, Glucuronides in anti-cancer therapy, Curr Med Chem Anti-cancer Agents, 3, 139, 10.2174/1568011033353470
Dachs, 2009, Bystander or no bystander for gene directed enzyme prodrug therapy, Molecules, 14, 4517, 10.3390/molecules14114517
Das, 2010, Codrug: An efficient approach for drug optimization, Eur J Pharm Sci, 41, 571, 10.1016/j.ejps.2010.09.014
Dhar, 2008, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles, Proc Natl Acad Sci USA, 105, 17356, 10.1073/pnas.0809154105
Dharap, 2005, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide, Proc Natl Acad Sci USA, 102, 12962, 10.1073/pnas.0504274102
Di Venosa, 2006, Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy, Int J Biochem Cell Biol, 38, 82, 10.1016/j.biocel.2005.08.001
Divaris, 1990, Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence, Am J Pathol, 136, 891
Fasinu, 2011, Diverse approaches for the enhancement of oral drug bioavailability, Biopharm Drug Dispos, 32, 185, 10.1002/bdd.750
Gadi, 2000, In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells, Gene Ther, 7, 1738, 10.1038/sj.gt.3301286
Gaullier, 1997, Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture, J Cancer Res, 57, 1481
Girardin, 2006, Membrane transporter proteins. a challenge for CNS drug development, Dialogues Clin Neurosci, 8, 311, 10.31887/DCNS.2006.8.3/fgirardin
Graf, 2012, Redox activation of metal-based prodrugs as a strategy for drug delivery, Adv Drug Deliv Rev, 64, 993, 10.1016/j.addr.2012.01.007
Gynther, 2008, Large neutral amino acid transporter enables brain drug delivery via prodrugs, J Med Chem, 51, 932, 10.1021/jm701175d
Hatanaka, 2004, Transport of amino acid-based prodrugs by the Na+- and Cl–-coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery, J Pharmacol Exp Ther, 308, 1138, 10.1124/jpet.103.057109
He, 1999, Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802, Clin Pharmacokinet, 37, 471, 10.2165/00003088-199937060-00003
Hughes, 1998, Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase, J Biol Chem, 273, 2322, 10.1074/jbc.273.4.2322
Huttunen, 2011, Prodrugs – from serendipity to rational design, Pharmacol Rev, 63, 750, 10.1124/pr.110.003459
Jana, 2010, Prodrug design to improve pharmacokinetic and drug delivery properties. challenges to the discovery scientists, Curr Med Chem, 17, 3874, 10.2174/092986710793205426
Johnston, 2001, Capecitabine. a novel agent for the treatment of solid tumors, Anticancer Drugs, 12, 639, 10.1097/00001813-200109000-00001
Juarranz, 2008, Photodynamic therapy of cancer Basic principles and applications, Clin Transl Oncol, 10, 148, 10.1007/s12094-008-0172-2
Kaakkola, 2000, Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease, Drugs, 59, 1233, 10.2165/00003495-200059060-00004
Khatri, 2007, Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer, Discov Med, 7, 39
Kim, 2010, Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex, Biomaterials, 31, 4592, 10.1016/j.biomaterials.2010.02.030
Kokil, 2010, Bioprecursor prodrugs. molecular modification of the active principle, Mini Rev Med Chem, 10, 1316, 10.2174/138955710793564179
Koukourakis, 2008, Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment. a review, Molecules, 13, 1897, 10.3390/molecules13081897
Li, 2008, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting, J Pharm Sci, 97, 1109, 10.1002/jps.21047
Mahato, 2011, Prodrugs for improving tumor targetability and efficiency, Adv Drug Deliv Rev, 63, 659, 10.1016/j.addr.2011.02.002
Martiniello-Wilks, 2004, Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer, J Gene Med, 6, 1343, 10.1002/jgm.629
Miwa, 1998, Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue, Eur J Cancer, 34, 1274, 10.1016/S0959-8049(98)00058-6
Müller, 2009, Prodrug administration for enhancing the bioavailability of drugs with low molecular solubility, Chem Diver, 6, 2071
Musiol, 2011, Prodrugs in photodynamic anticancer therapy, Curr Pharm Des, 17, 3548, 10.2174/138161211798194549
Pardridge, 2007, Brain drug development and brain drug targeting, Pharm Res, 24, 1729, 10.1007/s11095-007-9387-0
Patel, 2009, Getting into the brain. approaches to enhance brain drug delivery, CNS Drugs, 23, 35, 10.2165/0023210-200923010-00003
Peng, 1997, 5-Aminolevulinic acid-based photodynamic therapy. clinical research and future challenges, Cancer, 79, 2282, 10.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O
Pescovitz, 2000, Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients, Antimicrob Agents Chemother, 44, 2811, 10.1128/AAC.44.10.2811-2815.2000
Rautio, 2008, Prodrugs. design and clinical applications, Nat Rev Drug Discov, 7, 255, 10.1038/nrd2468
Rodriguez, 2006, Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells, Br J Pharmacol, 147, 825, 10.1038/sj.bjp.0706668
Rogers, 2005, An efficient synthesis of 5-aminolaevulinic acid (ala)-containing peptides for use in photodynamic therapy, Tetrahedron, 61, 6918, 10.1016/j.tet.2005.05.036
Salvetti, 1990, Newer ACE inhibitors. A look at the future, Drugs, 40, 800, 10.2165/00003495-199040060-00004
Schellmann, 2010, Targeted enzyme prodrug therapies, Mini Rev Med Chem, 10, 887, 10.2174/138955710792007196
Schukin, 2011, Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice, Pharmacol Rep, 63, 1093, 10.1016/S1734-1140(11)70628-4
Shi, 2012, Pt(IV) complexes as prodrugs for cisplatin, J Inorg Biochem, 107, 6, 10.1016/j.jinorgbio.2011.10.012
Sievers, 2003, Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg), Blood Cells Mol Dis, 31, 7, 10.1016/S1079-9796(03)00117-7
Silverman, 2004
Singh, 2011, Molecular chemotherapy and chemotherapy. a new front against late-stage hormone-refractory prostate cancer, Clin Cancer Res, 17, 4006, 10.1158/1078-0432.CCR-11-0248
Song, 2005, Amino acid ester prodrugs of the anticancer agent gemcitabine. synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport, Mol Pharm, 2, 157, 10.1021/mp049888e
Soul-Lawton, 1995, Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans, Antimicrob Agents Chemother, 39, 2759, 10.1128/AAC.39.12.2759
Springer, 2000, Prodrug-activating systems in suicide gene therapy, J Clin Invest, 105, 1161, 10.1172/JCI10001
Srinivas, 2011, The rationality for using prodrug approach in drug discovery programs for new xenobiotics. opportunities and challenges, Eur J Drug Metab Pharmacokinet, 36, 49, 10.1007/s13318-011-0035-z
Stella, 2007
Teicher, 2011, Antibody conjugate therapeutics. challenges and potential, Clin Cancer Res, 17, 6389, 10.1158/1078-0432.CCR-11-1417
Teicher, 2009, Antibody-drug conjugate targets, Curr Cancer Drug Targets, 9, 982, 10.2174/156800909790192365
Testa, 2009, Prodrugs; bridging pharmacodynamic/pharmacokinetic gaps, Curr Opin Chem Biol, 13, 338, 10.1016/j.cbpa.2009.04.620
Tietze, 2009, Antibody-directed enzyme prodrug therapy. a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies, Chem Biol Drug Des, 74, 205, 10.1111/j.1747-0285.2009.00856.x
Tsume, 2008, Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters, Molecules, 13, 1441, 10.3390/molecules13071441
Umapathy, 2004, Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB0,+, Pharm Res, 21, 1303, 10.1023/B:PHAM.0000033019.49737.28
Vytla, 2012, Prodrug approaches to reduce hyperexcitation in the CNS, Adv Drug Deliv Rev, 64, 666, 10.1016/j.addr.2011.11.007
Wu, 2009, A new classification of prodrugs. regulatory perspective, Pharmaceuticals, 2, 77, 10.3390/ph2030077
Yaltho, 2010, The use of gabapentin enacarbil in the treatment of restless legs syndrome, Ther Adv Neurol Disord, 3, 269, 10.1177/1756285610378059
Yu, 2011, Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro, PLoS One, 6, e24077, 10.1371/journal.pone.0024077
Zhang, 2010, Aptamers selected by cell-SELEX for application in cancer studies, Bioanalysis, 2, 907, 10.4155/bio.10.46